With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The poultry medicine/pharmaceuticals market valued at US$ 4.73 billion in 2023, is forecasted to grow at a robust CAGR of 5.9%, reaching US$ ...